Pairwise matches early-stage biotech companies with specialist boutique CROs — by indication, phase, and fit. Not a database. A decision engine.
IQVIA, ICON, Syneos prioritize Big Pharma accounts. Early-stage biotechs get junior staff, slow responses, and pricing built for Fortune 500 pipelines. McKinsey confirmed it: emerging biotechs are the least-satisfied segment of the CRO market.
The best specialized CROs — focused on rare disease, specific oncology indications, early-phase complexity — have no BD budget and no directory presence. They exist in conference hallways and word-of-mouth networks that first-time founders never access.
Existing platforms are procurement databases, not matchmakers. They list every CRO equally — regardless of indication fit, team stability, capacity, or track record with trials like yours. The decision is left entirely to the founder, who has no clinical ops experience.
Pairwise builds structured profiles for hundreds of boutique CROs — therapeutic area, trial phase capability, geography, team size, past performance, and capacity signals. Biotech founders answer five questions about their trial, and Pairwise returns ranked, explained matches.
Every CRO in Pairwise is profiled by hand. We track therapeutic focus, trial phase range, team headcount, geographic coverage, client size range, and capacity status — so you know who is actively taking on new work.
Not a search filter — a matching algorithm that weighs your indication, phase, timeline, geography, and budget against structured CRO profiles. Results are ranked and explained, not just returned.
Boutique CROs often have bandwidth and appetite that never shows up in RFPs. Pairwise surfaces real-time capacity signals so you're not approaching firms at full capacity or with mismatched specialization.
Pairwise facilitates warm introductions, not cold transactions. We introduce you to the right contact at each CRO, reducing BD friction and increasing response rates for both sides of the match.
"The best CRO for your trial isn't the most famous one. It's the one that has done exactly your trial before, wants to do it again, and has the bandwidth to do it right."
Pairwise was built on a simple conviction: early-stage biotechs deserve the same quality of CRO partnership that late-stage pharma gets — and they currently don't. The market is too fragmented and informationally opaque for founders who are, more often than not, doing their first drug development program.
We'd rather have 200 perfectly profiled CROs than 20,000 unverified listings.
A 15-person rare-disease specialist will outperform a 5,000-person generalist for your trial. Every time.
We're not a vendor list. We're a partnership layer. Our success is measured by long-term CRO-sponsor fit.
Pairwise exists so that no early-stage biotech ever has to choose a CRO based on a Google search again.